BioAsset

Insights / All articles

Industry Trends

From the Space Race to the Biotech Race: China Guards Its Lead

By Judy Dalati, Research Analyst at BioAsset · 5 slides

Recruiting foreign talent helped the U.S. win the Space Race. China is making sure that can’t happen in biotech.

On Oct. 16, 2026, Beijing proposed blocking foreign acquisitions of proprietary cell and gene therapy (CGT), siRNA, and pathogen gain-of-function platforms. Put simply, China wants to stop foreign companies from buying its most valuable biotech “engines.”

What the engines are

Why CGT and siRNA? Because that’s where China is winning. In stem cell therapies, gene therapies, and RNA-based medicines, China accounts for almost one-third of the global pipeline in Phase I and II clinical development. China is banning the sale of exactly what it’s winning at.

Licensing is still open, however, so U.S. companies can rent China’s drugs but can’t buy the machine. The real story is that China has gone from copying drugs to inventing them, and now it’s protecting that lead.

China is catching up fast

According to McKinsey, China had just 4% of the world’s innovative drug pipeline in 2015, rising to around 30% by 2025. The U.S. share declined from 47% in 2018 to 36% by 2026. A gap of 39 points between the two in 2018 is down to 6 points.

In early-stage science, China now leads. Goldman Sachs estimates Chinese companies contributed 46% of all new drug molecules entering human trials in the first half of 2025, compared with 17% a decade earlier. China has also passed the U.S. in clinical trials: in 2024 it listed more than 7,100 trials in the WHO registry, versus about 6,000 for the U.S.

Speed is China’s advantage. With a 30-working-day review to start trials and high patient density, Phase I trials that often take two years in the U.S. are frequently completed in nine months in China. But China’s trials are mostly local: 70%+ are China-only. The U.S. still leads in global reach.

The money

Big Pharma needs new drugs, and fast. When a drug’s patent expires, competitors can sell cheap copies, known as generics, and the original drug’s sales crash. Deloitte estimates Big Pharma could lose $236B in revenue by 2030 as patents expire on 190 drugs.

So Big Pharma is shopping in China. China’s out-licensing deal value grew from $51.9B in 2024 to $135.7B in 2025, and China held about 50% of global out-licensing deal value in 2025. Chinese assets have traded at 40-50% lower deal values than Western equivalents, but China’s leverage is growing: average upfront payments rose from $52M in 2022 to $172M in 2026, which is 3.3x more cash upfront.

The difference between buying and renting matters here. Acquire a platform and you own 100% of the profits plus every future drug the platform creates. License a drug and you pay a cut of every sale, and the platform stays in China. The new rule removes the “acquire” option for China’s best platforms. AstraZeneca’s $1B Gracell buyout, for example, likely couldn’t happen today.

What this means for the U.S.

After WWII, the U.S. ran Operation Paperclip, bringing German rocket scientists like Wernher von Braun to America. He later led the development of the Saturn V rocket that took Apollo to the Moon. Acquiring the minds behind the rockets helped the U.S. win. China is making sure no one can do that to its biotech platforms.

Who wins and who loses is my opinion. Big Pharma still gets Chinese drugs, but as a renter paying fees, not an owner, which leads to less control and thinner margins. For U.S. biotechs with CGT and siRNA platforms, if China can’t be bought, Western platforms become rarer and possibly more valuable. For the U.S. as a whole, the more dependent it gets on licensing from China, the more leverage China has over future medicines and innovations. That’s why U.S. lawmakers proposed the Biotech Investment National Security Act to scrutinize Chinese biotech deals.

My outlook, again an opinion: the U.S. is no longer clearly ahead on early-stage innovation. Its advantage now is capital, global approvals, and the world’s most profitable drug market. The comment deadline on China’s draft rule was Nov. 15, 2026.

In the Space Race, the winner was whoever controlled the talent. In biotech, it’s whoever controls the platforms.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.